Mohamad Mohty

From Wikitia
Jump to navigation Jump to search
Mohamad Mohty
Mohamad Mohty.jpg
Alma mater
  • University of Montpellier
  • Aix-Marseille University
Scientific career
Fields
  • Malignant hematology
  • stem cell transplantation
  • cellular therapy
Institutions
  • Sorbonne University
  • Saint-Antoine Hospital
  • Assistance-publique des Hôpitaux de Paris (AP-HP)[1]

Mohamad Mohty is a French hematologist and researcher currently holds the position of Full Professor of Hematology and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He is also the head of a translational research team[2] at the Saint-Antoine Research Centre in Paris.[3][4][5]

Dr. Mohty has made significant contributions to the field of hematology and immunobiology, particularly stem cell transplantation,[6] leukemia, and myeloma.[7] In addition to his academic and research roles. He is actively involved in numerous professional societies and organizations, including the European Society for Blood and Marrow Transplantation (EBMT), and the International Academy for Clinical Hematology (IACH).[8][9][10]

Education

Dr. Mohty received his medical degree from the University of Montpellier (M.D., 2000), France, and his Ph.D. from the University of Marseille, France (2003). He also undertook post-doctoral work at the Hematology Department of Imperial College, Hammersmith Hospital in London, UK. In 2005, he obtained his Habilitation to Direct Research (Habilitation à diriger les Recherches, HDR), from the Université de la Méditerranée, Marseille, France, which is the highest diploma that can be granted by a French university.

Since 2008, he has been a Professor of clinical hematology and (since 2012) Head of the Clinical Hematology and Cellular Therapy Department at the Saint-Antoine Hospital, Sorbonne University, Paris, France. From 2008 to 2012, he was Professor of Clinical Hematology and head of the stem cell program at the Faculty of Medicine and University Hospital of Nantes, France. From 2002 to 2007, he was Senior Consultant and Associate Professor of Hematology at the Faculty of Medicine of Marseille, and the Regional Cancer Centre Institut Paoli-Calmettes, Département d’Hématologie, Unité de Transplantation et de Thérapie Cellulaire, Marseille, France.[11]

Career

Dr. Mohty started his career in academia with a focus on translational research related to the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs, and hypomethylating agents. His research has also included the development of reduced-toxicity conditioning regimens, immunotherapy, and other aspects of therapy for acute leukemia and multiple myeloma.[12] More recently, he pioneered a cutting-edge research dedicated to the modulation of the microbiota[13] in patients with hematological malignancies.

Dr. Mohty is known for his extensive contributions to the field, including publishing over 900 peer-reviewed[14] articles in leading hematology and immunology journals such as the New Engl. J Med, Blood, J Clin Oncol, The Lancet, The Lancet Oncology, The Lancet Haematology, Nature Reviews, and many other prestigious journals. According to Scopus, he has 33 334 citations by 20,436 documents, worked with 5342 co-authors and has an h-index of 89.[15][16]

In 2015, Dr Mohty was ranked among the ten most productive authors in hematology worldwide over the last ten years (Kamble et al., Bibliometric Analysis of Hematology during 2004-2013, J. Adv. in Library and Information Sci., 4: 21-25; 2015). He also has been invited to present over five hundred lectures around the world (more than 70 countries visited) related to hematology (especially multiple myeloma), immunology, oncology, and stem cell transplantation/cellular therapy.[17]

Dr Mohty has strong expertise in clinical research and deep knowledge in the field of stem cell transplantation, cellular therapy, and therapy of leukemia and multiple myeloma. Over the last 10 years, he played a key role in the approval of different hematology drugs. He served as the principal investigators for >10 major national protocols in the field of hematology, cellular therapy and stem cell transplantation (equivalent to large NIH grants), and he was the co-investigator of >50 national and international clinical research protocols.[18]

Driven by a strong entrepreneurial spirit, Dr Mohty is regularly consulted by biotechs, clinical stage hematology/oncology companies and industry leaders focusing on treating blood cancers. He has been acting as the key scientific and clinical advisor for different companies (assistance with interactions with EMA, FDA, regulatory bodies, payor organizations, SAB, etc.)

He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation[19] and Clinical Hematology International and as an associate editor for Leukemia, European Journal of Haematology, and Blood Cancer Journal. He is also a regular reviewer for numerous other reputable journals and serves on the editorial board of Blood and Haematologica. Dr. Mohty's extensive expertise in the field of hematology has made him a highly sought-after speaker and consultant.[20]

Dr Mohty has been actively involved in the scientific community and as a member of societies focused on hematology, immunology, oncology, and stem cell transplantation. He was the Scientific Chair of the 37th annual meeting of EBMT held in Paris April 3-7, 2011. In 2010 and 2017, he was invited by ASH to be part of the educational program. He served as a member of the Steering Committee on Practice Guidelines for ASBMT.

Dr. Mohty has held various leadership positions in professional societies, he is past-president of the European Society for Blood and Marrow Transplantation (EBMT; 2014-2018) and past chairman of the Acute Leukemia Working Party (ALWP; 2010-2014 and 2018-20222) of the EBMT. He is also the founder and current chairman of the International Academy for Clinical Hematology (IACH; 2018)[21] and a board member of the Intergroupe Francophone du Myelome (IFM; since 2005).[22]

He also a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO),[23] Société Française d’Hématologie (SFH),[24] Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC),[25] and the European Hematology Association (EHA).[26]

Awards and Honors

  • Prize of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), 2000
  • Prize of the Club Francophone des Cellules Dendritiques (CFCD), 2002
  • Prize of the Assoc. Méditerranéenne pour le Développement de la Transplantation (AMDT), 2003
  • Finalist for “Trophées du festival de la Science de la région PACA”, 2003 and 2004
  • Prize of the Société Française d’Hématologie, (Prix Laurette Fuguain),[27] 2004
  • Prize of the Université de la Méditerranée (Marseille), 2004
  • Prize “PARI” of the SFGM-TC, 2007
  • “Nobel Conference Lecturer”, Karolinska 2012[28]
  • Prize of the China-France Boxiao Foundation, 2013
  • Pierre Stryckmans award (Belgium), 2016[29]
  • Since the 1st of Jan. 2021, Dr Mohty was knighted as “chevalier de la légion d’honneur” (The Legion of Honor is the highest French decoration and one of the most famous in the world. For two centuries, it has been presented on behalf of the president of the republic of France to reward the most deserving citizens in their field of activity - https://www.legiondhonneur.fr/en/).[30][31][32][33]

References

  1. ↑ "Pr MOHAMAD MOHTY". www.aphp.fr (in français). Retrieved 11 March 2023.
  2. ↑ "Equipe Mohamad Mohty". Equipe Mohamad Mohty (in français). Retrieved 11 March 2023.
  3. ↑ Zamecnik, Adam (29 April 2022). "Access to CAR-T therapies in Central and Eastern Europe in "catch-up" mode". Pharmaceutical Technology. Retrieved 11 March 2023.
  4. ↑ "MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting". www.businesswire.com. 11 December 2022. Retrieved 11 March 2023.
  5. ↑ "mohamad-mohty". www.hme-forum.com. Retrieved 11 March 2023.
  6. ↑ "Rehabilitation Association for Hematopoietic cell transplant". cgvhd. Retrieved 11 March 2023.
  7. ↑ "Reviewer Acknowledgment". The Oncologist. 1 December 2021. pp. e2310–e2313. doi:10.1002/onco.13986. Retrieved 11 March 2023.
  8. ↑ "Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis". aacrjournals.org. Retrieved 11 March 2023.
  9. ↑ "Discover more at EBMT". www.ebmt.org. Retrieved 11 March 2023.
  10. ↑ "Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness". ashpublications.org. Retrieved 11 March 2023.
  11. ↑ Kalif, Yaniv. "Homepage". International Academy for Clinical Hematology (IACH). Retrieved 11 March 2023.
  12. ↑ Lannes, Romain; Samur, Mehmet; Perrot, Aurore; Mazzotti, Celine; Divoux, Marion; Cazaubiel, Titouan; Leleu, Xavier; Schavgoulidze, Anaïs; Chretien, Marie-Lorraine; Manier, Salomon; Adiko, Didier; Orsini-Piocelle, Frederique; Lifermann, François; Brechignac, Sabine; Gastaud, Lauris; Bouscary, Didier; Macro, Margaret; Cleynen, Alice; Mohty, Mohamad; Munshi, Nikhil; Corre, Jill; Avet-Loiseau, Hervé (7 November 2022). "In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations". Journal of Clinical Oncology. pp. JCO.21.01987. doi:10.1200/JCO.21.01987. Retrieved 11 March 2023.
  13. ↑ "December 11, 2022: MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting". MaaT Pharma. 11 December 2022. Retrieved 11 March 2023.
  14. ↑ "National Library of Medicine". PubMed. Retrieved 11 March 2023.
  15. ↑ "Scopus preview - Mohty, Mohamad - Author details - Scopus". www.scopus.com. Retrieved 11 March 2023.
  16. ↑ "Recap: Improving Outcomes in Newly Diagnosed Multiple Myeloma". Cancer Network. Retrieved 11 March 2023.
  17. ↑ "Second Transplant vs Donor Lymphocyte Infusion in Relapsed AML". www.medpagetoday.com. 12 July 2018. Retrieved 11 March 2023.
  18. ↑ "Mohamad Mohty | Videos & Research". VJHemOnc. Retrieved 11 March 2023.
  19. ↑ "About the Editors | Bone Marrow Transplantation". www.nature.com. Retrieved 11 March 2023.
  20. ↑ "Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD". OncLive. Retrieved 11 March 2023.
  21. ↑ "Discover more at EBMT". www.ebmt.org. Retrieved 11 March 2023.
  22. ↑ "Bureau de l'IFM mars 2023". www.myelome.fr (in français). Retrieved 11 March 2023.
  23. ↑ Mohty, Mohamad; Malard, Florent (20 June 2021). "Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation". Journal of Clinical Oncology. pp. 1951–1954. doi:10.1200/JCO.21.00622. Retrieved 11 March 2023.
  24. ↑ "Accueil | Société Française d'Hématologie". sfh.hematologie.net. Retrieved 11 March 2023.
  25. ↑ "Accueil". www.sfgm-tc.com. Retrieved 11 March 2023.
  26. ↑ Association (EHA), The European Hematology. "Home". The European Hematology Association (EHA). Retrieved 11 March 2023.
  27. ↑ "Liste-Prix-Laurette-Fugain" (PDF). laurettefugain.org. Retrieved 11 March 2023.
  28. ↑ "Förslag till program för Nobel Symposium, preliminärt den 7" (PDF). nobelprizemedicine.org. Retrieved 11 March 2023.
  29. ↑ "twitter.com/HallekMichael/status/1091398783588536320/photo/2". Twitter. Retrieved 11 March 2023.
  30. ↑ "Mohamad Mohty nominated as "Chevalier de la Légion d'honneur" in France". EBMT. Retrieved 11 March 2023.
  31. ↑ "Décret du 31 décembre 2020 portant promotion et nomination dans l'ordre national de la Légion d'honneur". www.legifrance.gouv.fr. Retrieved 11 March 2023.
  32. ↑ "Handbook of Multiple Myeloma". amazon.fr. Retrieved 11 March 2023.
  33. ↑ "Clinical Hematology International". Springer. Retrieved 11 March 2023.

External links

Retrieved from "https://wikitia.com/index.php?title=Mohamad_Mohty&oldid=171534"